STOCK TITAN

Aclarion Inc - ACON STOCK NEWS

Welcome to our dedicated news page for Aclarion (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aclarion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aclarion's position in the market.

Rhea-AI Summary
Aclarion, a healthcare technology company, has announced that Dean Karahalios, M.D., will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain. The company will also be attending the ISASS 2023 conference in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.93%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary
Aclarion, a healthcare technology company, announced a post-market trial to evaluate the role of Nociscan in diagnosing and treating chronic low back pain. The trial will be led by Dr. Nicholas Theodore of Johns Hopkins University. Nociscan has shown promise in objectively measuring pain-generating biomarkers in the spine. The trial aims to expand on previous successful outcomes and establish Nociscan as a standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.16%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
72.97%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
Aclarion Inc

Nasdaq:ACON

ACON Rankings

ACON Stock Data

2.33M
1.93M
2.32%
1.66%
2.22%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States
Broomfield